Rybelsus relaunches in the US as the reformulated Ozempic pill

Novo Nordisk began selling its reformulated oral semaglutide nationwide on May 4, 2026, under the Ozempic name, effectively phasing out the Rybelsus brand in the United States ^[3]. The pill is approved for adults with type 2 diabetes to improve blood sugar control alongside diet and exercise, and to reduce the risk of major cardiovascular events in people at increased risk ^[1].

The biggest practical change is the numbers on the label. Rybelsus came in 3 mg, 7 mg and 14 mg tablets ^[1]. The new version, known as the R2 formulation, comes in 1.5 mg, 4 mg and 9 mg ^[1][3]. The FDA approved that formulation in December 2024 ^[3]. Changes to the excipients — the inactive ingredients — raise semaglutide exposure by roughly 25%, so 1.5 mg of the new pill is bioequivalent to 3 mg of the old one, 4 mg matches 7 mg, and 9 mg matches 14 mg ^[3]. Novo Nordisk says the new pill is smaller and more bioavailable, with the same efficacy and safety profile as before ^[1].

Pharmacy Times stresses that the two formulations are not interchangeable milligram for milligram, and that patients should not switch between them without a prescriber's guidance ^[3]. It also notes a counseling point pharmacists expect to repeat often: a lower number on the bottle does not mean a weaker medicine ^[3].

What it costs

Through NovoCare Pharmacy, self-pay prices are $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg, where one month is defined as a single bottle of 30 tablets ^[2][4]. Those prices apply to home delivery or local pharmacy pickup with a savings offer, and eligibility and restrictions apply ^[4]. Novo Nordisk says it can change or cancel the program at any time ^[2].

For people with commercial insurance, Novo Nordisk advertises a copay of as little as $25, subject to a maximum savings of $100 per month, with government beneficiaries excluded ^[2][4]. The sources describe this slightly differently: Medical News Today reports insured patients "may" pay $25 for up to a 3-month supply ^[1], while NovoCare's own materials describe $25 per month for up to 3 months ^[2]. The injectable Ozempic pen is priced separately — $199 a month for the first two months of 0.25 mg or 0.5 mg for new patients, then $349 a month for 0.25 mg, 0.5 mg or 1 mg and $499 a month for 2 mg ^[2][4].

Novo Nordisk says the pill is available through more than 70,000 U.S. pharmacies plus select telehealth providers and mail order ^[1].

Why it matters for patients

If you filled Rybelsus, your next refill may arrive with a different brand name and a different milligram number even though nothing about your treatment has changed ^[3]. That is a realistic setup for confusion at the counter, and it is worth confirming with a pharmacist or prescriber that the strength on the new bottle corresponds to the old one.

The administration rules have not changed. All oral semaglutide must be taken first thing in the morning on an empty stomach, with no more than 4 ounces of plain water, and at least 30 minutes before food, other drinks or other oral medicines ^[3]. Oral bioavailability is still under 1%, which is why the timing rules matter so much ^[3].

The trade-offs between pill and injection also stand. Research generally shows injectable semaglutide produces larger HbA1c reductions than the oral form in type 2 diabetes, and adverse events occur more frequently with oral semaglutide ^[1]. Nausea, diarrhea, vomiting and constipation remain the most common side effects; all semaglutide products carry a boxed warning for thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 ^[3].

One more distinction: the Ozempic pill is approved only for type 2 diabetes and cardiovascular risk reduction, not weight loss ^[3]. A separate 25 mg oral semaglutide, branded Wegovy, was approved in December 2025 for chronic weight management, based on the OASIS 4 trial, in which participants lost a mean 13.6% of body weight at 64 weeks versus 2.2% on placebo ^[3].

What happens next

Novo Nordisk's limited-time pen pricing for new patients runs through December 31, 2026 ^[4]. How long remaining Rybelsus-branded stock will circulate in pharmacies is not stated in these sources.